Mark Foley: Sure. The deeper versus wider strategy is something that we’ve been very consistent with going back to the RHA. If you look at it, the onboarding pace of new customers on the RHA fillers has been pretty consistent over time, where we’ve added roughly 500 new accounts per quarter, all with the goal of let’s make sure that when we introduce somebody to our products that they get trained the right way, they get the right information to be successful, and that, again, we can drive stickiness. And so that’s been a long term part of our prestige strategy. And so that’s very consistent with what we plan to do with DAXXIFY. And as we’ve stated previously, we plan to target those accounts that we have an existing RHA relationship with first, because we have a relationship with them.
And we think anytime you’re introducing a new product, making sure that that onboarding process is robust, engaged and that we are working to get it integrated into the practice versus just the sampling thing is the right strategy. And so if you look at our PrevU program, it was really designed to give us additional insights into practice integration, clinical outcome, real word usage, so that when we did go to full commercial launch, which we will kick off later this quarter towards the end of March. We can take some of those learnings and make tweaks or modifications to the information that we share. And so we’re very pleased with how PrevU is going the learnings that we have and we continue to be very much on target for our overall launch plan and strategy.
With regards to the €“ and I don’t know that we’ve ever said that that’s a headwind, I just think that that’s always been the strategy and fits very well in that prestige of targeting those accounts. With regards to the PrevU, as you’re aware, we rolled out the PrevU program to approximately 400 accounts in December. These accounts are €“ accounts that were very anxious and eager to get DAXXIFY, had a lot of patience, ready to use the product when they brought it in. And we’ve certainly had a fair bit of reorders on those accounts. But it’s really provided that platform for learning and education to inform the broader market launch, which we plan to roll out again in late March.
Annabel Samimy: Great. And will you give €“ be giving us reorder metrics going forward?
Mark Foley: Well, we haven’t historically done that with RHA. We’ve talked more about account side of it. We’re very early in that side of it. And so we’ll continue to assess what we think makes sense as we have more data to inform that process. But if we look at what we’ve historically done, we’ve given the number of accounts that we have from an aesthetics portfolio standpoint. So I think that’s a good baseline. And then as we get more information, but we’re super early, we really like what we’re seeing and it’s very consistent with the strategy that we’ve mapped out. And so as we have information that we think is informed of going forward, we’re €“ we’ll look to share that.
Annabel Samimy: Okay. And then one last question, if I can switch to therapeutically. So obviously, you’re going to be approaching a potential approval this year. Can you talk about some of the commercial and specifically payer efforts that you have underway on how you’ll be, I guess, pitching a premium product to market that doesn’t always use logic and pharmacoeconomics, when they’re making their access decisions? So if you could just help us understand that play out.
